Poll results: Preferred treatment plans for mild-stage POAG

Article

See our latest poll results

Optometry Times® polled our audience with the following question from January 28, 2022 to February 11, 2022:​ If diagnosed with mild-stage POAG, what would be your preferred treatment plan?

The poll appeared on optometrytimes.com and was promoted on social media channels. Results show the majority of responding ODs would initiate medical therapy with a topical glaucoma medication.

22 ODs responded, in total. Of these:

  • 15 responded "Initiate medical therapy with a topical glaucoma medication"
  • 4 responded "Have selective laser trabeculoplasty (SLT)"
  • 3 responded "Have a minimally invasive glaucoma surgery (MIGS)"

Check out our latest poll: What is your big goal for 2022?

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
© 2025 MJH Life Sciences

All rights reserved.